The efficacy of high-dose melphalan with autologous peripheral blood stem cell transplantation in patients with multiple myeloma

Yonsei Medical Journal

Volumn 44, Issue 5, 2003, Pages 800-810

  Lee, Jae Lyun ^a,b   Kim, Sung Bae ^a   Lee, Gyeong Won ^a,c   Ryu, Min Hee ^a   Kim, Eunkyoung ^a   Kim, Shin ^a   Kim, Woo Kun ^a   Lee, Jung Shin ^a   Kim, Sang Hee ^a   Suh, Cheolwon ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

^c Gyeongsang National University School of Medicine   (South Korea)

Author keywords

Hematopoietic stem cell transplantation; Multiple myeloma; Transplantation, autologous

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LIVER DYSFUNCTION; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PREDICTION; SURVIVAL TIME; VOMITING;

EID: 0242490869     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2003.44.5.800     Document Type: Article

References (27)

1. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 1992;10:334-42.
2. Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, et al. Multiple myeloma: VMCP/BAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991;9:444-8.
3. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet 1983;2:822-4.
4. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, et al. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759-63.
5. Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 1995;85:3077-85.
6. Fermand JP, Chevret S, Ravaud P, Divine M, Leblond V, Dreyfus F, et al. High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993;82:2005-9.
7. Blade J, Sam Miguel KF, Montserrat F, Alcala A, Maldonado J, Garcia-Conde J, et al. Survival of multiple myeloma patients who are potential candidates for early high dose therapy intensification/ autotransplantation and who were conventionally treated. J Clin Oncol 1996;14:2167-73.
8. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
9. Barlogie B, Jagannath S, Vesole D, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy of previously untreated multiple myeloma. Blood 1997;89:789-93.
10. Lee JH, Bang S, Lee S, Kim HS, Ahn JS, Cho EK, et al. High dose chemotherapy with autologous stem cell transplantation in multiple myeloma. Korean J Hematol 1999;34:306-16.
11. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
12. Song HH, Lee JH, Park JB, Choi SJ, Kim JK, Kim SB, et al. Prognostic factors affecting response to chemotherapy and survival duration in Korean patients with multiple myeloma. Korean J Med 2000;58:83-90.
13. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;36:1657-64.
14. Yang SH, Kim TY, Kim BK, Ko YW, Kwak DS, Kim NK, et al. A statistical study of multiple myeloma in Korea. Korean J Hematol 1995;30:345-61.
15. Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the EBMT. Bone Marrow Transplant 2001;27:511-5.
16. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long term follow-up results. Br J Haematol 1998;102:495-502.
17. Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995;85: 1596-602.
18. Davies FE, Rawstron AC, Owen RG, Morgan GJ. Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Haematol 2002;15:197-222.
19. Harousseau JL. Role of transplantation in myeloma, In: Broudy VC, Abkowitz JL, Vose JM, Bajus JL, editors. Hematology 2002, American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2002. p.221-7.
20. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomidedexamethasone after intensive chemotherapy. Ann Oncol 2002;13:1116-9.
21. Massaia M. Idiotype vaccination of myeloma patients after chemotherapy. Acta Oncol 2000;39:807-8.
22. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000;6:621-7.
23. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755-60.
24. Attal M, Harousseau JL. Autologous peripheral blood progenitor cell transplantation for multiple myeloma. Best Pract Res Clin Haematol 1999;12:171-91.
25. Stewart AK, Schiller G, Vescio K. CD34 selection does not prolong disease free or overall survival in myeloma patients undergoing autologous stem cell transplants: results of a Phase III study. [abstract] Blood 1999;94 Suppl 1:714
26. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
27. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-71.